We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Edwards Lifesciences, a maker of heart valve technologies, has entered into
an agreement with St. Jude Medical resolving patent infringement litigation
initiated by Edwards in June 2000 related to certain Edwards patents in the
areas of heart valve repair and replacement.
Laser and light-based medical devices company Lumenis has announced an agreement
with Eclipse Medical, its distributor for aesthetic products in four states
in the South Central U.S.
Sysmex announced the development of a new technology based on a cell cycle profiling for diagnosis of the risk of recurrence in patients with early-stage cancer.
Corgenix Medical, due to the lack of progress toward the completion of the $6
million merger-related financing and the expiration of key dates within the
agreement and plan of merger, decided to terminate the planned merger with Genesis
Bioventures.
Enpath Medical has reported that the FDA requested more clinical data regarding
the company's Myopore Rx steroid lead before the agency will consider the company's
request for marketing clearance.
CryoCath, a maker of cryotherapy products to treat cardiovascular disease, has
announced that Vivek Reddy of the Massachusetts General Hospital presented additional
data on a human feasibility study using the company's proprietary Arctic Circler
Balloon catheter to treat atrial fibrillation (AF).
CABG Medical announced that the underwriters of the company's recent initial
public offering of its common stock have exercised in full their over-allotment
option to purchase an additional 825,000 shares of the company's common stock
at a price of $5.50 per share, before deducting underwriting discounts and commissions.
Voice Diary has announced it is reviewing its strategic plan and is considering
alternatives to expand its core technology and add additional lines of products
through strategic acquisitions or mergers.
Terumo has announced payment of damages, in the amount of 590,869 euros, by
Biosphere Medical, in accordance with the judgment rendered in favor of Terumo
Europe Nov. 18, 2004.